ARS

ARS is currently developing a needle-free nasal spray designed to consistently deliver a pharmacodynamic exposure of epinephrine that is similar to existing treatments. Our nasal spray may help reduce hesitation and allow patients to confidently administer when needed... Patient and Caregiver preparedness to act quickly and confidently during a severe allergic reaction is imperative. Hesitation can lead to worse clinical outcomes and can be fatal. ARS is committed to transforming the way we think about and use life-saving epinephrine... Our Board of Directors is charged both with guiding our company and advocating on behalf of the patients and caregivers we serve.

Primary location: San Diego United States